JP7631191B2 - Ｅ３リガーゼの共有結合による標的化 - Google Patents

Ｅ３リガーゼの共有結合による標的化 Download PDF

Info

Publication number
JP7631191B2
JP7631191B2 JP2021519602A JP2021519602A JP7631191B2 JP 7631191 B2 JP7631191 B2 JP 7631191B2 JP 2021519602 A JP2021519602 A JP 2021519602A JP 2021519602 A JP2021519602 A JP 2021519602A JP 7631191 B2 JP7631191 B2 JP 7631191B2
Authority
JP
Japan
Prior art keywords
rnf114
nimbolide
cells
231mfp
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021519602A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020076996A5 (https=
JP2022512643A (ja
JP2022512643A5 (https=
Inventor
スプラドリン，ジェシカ
ワード，カール・シー
ノムラ，ダニエル・ケイ
シルル，マルクス
タラリコ，ジョン・エイ
マッケナ，ジェフリー
マイモニ，トーマス・ジョン
フー，シールイ
Original Assignee
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア, ノバルティス アーゲー filed Critical ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Publication of JP2022512643A publication Critical patent/JP2022512643A/ja
Publication of JPWO2020076996A5 publication Critical patent/JPWO2020076996A5/ja
Publication of JP2022512643A5 publication Critical patent/JP2022512643A5/ja
Priority to JP2025017433A priority Critical patent/JP2025072508A/ja
Application granted granted Critical
Publication of JP7631191B2 publication Critical patent/JP7631191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021519602A 2018-10-09 2019-10-09 Ｅ３リガーゼの共有結合による標的化 Active JP7631191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017433A JP2025072508A (ja) 2018-10-09 2025-02-05 Ｅ３リガーゼの共有結合による標的化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743337P 2018-10-09 2018-10-09
US62/743,337 2018-10-09
PCT/US2019/055461 WO2020076996A1 (en) 2018-10-09 2019-10-09 Covalent targeting of e3 ligases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017433A Division JP2025072508A (ja) 2018-10-09 2025-02-05 Ｅ３リガーゼの共有結合による標的化

Publications (4)

Publication Number Publication Date
JP2022512643A JP2022512643A (ja) 2022-02-07
JPWO2020076996A5 JPWO2020076996A5 (https=) 2022-10-18
JP2022512643A5 JP2022512643A5 (https=) 2022-10-18
JP7631191B2 true JP7631191B2 (ja) 2025-02-18

Family

ID=70164411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519602A Active JP7631191B2 (ja) 2018-10-09 2019-10-09 Ｅ３リガーゼの共有結合による標的化
JP2025017433A Pending JP2025072508A (ja) 2018-10-09 2025-02-05 Ｅ３リガーゼの共有結合による標的化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017433A Pending JP2025072508A (ja) 2018-10-09 2025-02-05 Ｅ３リガーゼの共有結合による標的化

Country Status (5)

Country Link
US (2) US12161648B2 (https=)
EP (1) EP3863642A4 (https=)
JP (2) JP7631191B2 (https=)
CN (2) CN113164495B (https=)
WO (1) WO2020076996A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183600A1 (en) 2018-03-23 2019-09-26 The Regents Of The University Of California Methods and compounds for targeted autophagy
GB202005876D0 (en) * 2020-04-22 2020-06-03 Univ Dundee Protein degradation
JP7774612B2 (ja) * 2020-07-30 2025-11-21 サノフイ アクリルアミド置換インダン化合物およびその治療的使用
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
CN117042765A (zh) * 2021-01-08 2023-11-10 德克萨斯大学系统董事会 印苦楝内酯类似物及其使用方法
US20250276069A1 (en) * 2021-03-04 2025-09-04 The Scripps Research Institute Heterobifunctional compositions for targeted protein degradation and methods for their use
WO2022201162A1 (en) * 2021-03-25 2022-09-29 Technion Research & Development Foundation Limited Rnf4 targeting compounds and uses thereof
CN113527270B (zh) * 2021-07-16 2024-03-01 河南大学 一种靶向单酰基甘油脂肪酶的protac分子的医药中间体、制备方法及应用
CN116676273A (zh) * 2022-02-22 2023-09-01 中国科学院深圳先进技术研究院 一种蛋白水解靶向流感病毒及其制备方法和应用
CN114560908B (zh) * 2022-03-11 2024-10-25 国家纳米科学中心 一种多肽protac分子及其制备方法和应用
CN115417913B (zh) * 2022-08-26 2024-10-29 天津医科大学 靶向雌激素受体的谷胱甘肽响应protac降解剂的制备方法及应用
TW202416958A (zh) * 2022-10-13 2024-05-01 南韓商韓美藥品股份有限公司 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof
CN117263865B (zh) * 2023-08-04 2026-03-27 南开大学 以6,6-二甲基双环[3.1.1]-2-甲胺为疏水基团的蛋白降解剂及其制备方法、药物组合物和应用
WO2025226951A1 (en) * 2024-04-24 2025-10-30 Novartis Ag Molecular glue degrader compounds and uses thereof
CN119331047B (zh) * 2024-10-09 2025-09-30 重庆医科大学 一种蛋白水解靶向嵌合体及其制备方法
CN119405823B (zh) * 2024-11-15 2025-10-21 湖南大学 一种基于g四链体rna的蛋白降解靶向嵌合体及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180417A1 (en) 2016-04-12 2017-10-19 The Regents Of The University Of Michigan Bet protein degraders
WO2018052945A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2020146779A1 (en) 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171074A1 (en) * 2002-10-17 2004-09-02 Mount Sinai Hospital Structures of substrate binding pockets of SCF complexes
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN101928747B (zh) 2010-08-31 2012-08-08 中国人民解放军第二军医大学 E3泛素连接酶chip在脑胶质瘤疾病中的应用
US20150119435A1 (en) * 2012-05-11 2015-04-30 Yale University Compounds useful for promoting protein degradation and methods using same
CN104017879A (zh) * 2014-06-16 2014-09-03 山东大学 Fbxo31基因及其相关产物在制备胃癌诊断试剂中的应用
US11542500B2 (en) * 2015-05-29 2023-01-03 The Trustees Of The University Of Pennsylvania TRIM11 for degradation of protein aggregates
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2017180417A1 (en) 2016-04-12 2017-10-19 The Regents Of The University Of Michigan Bet protein degraders
WO2018052945A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
WO2020146779A1 (en) 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY

Also Published As

Publication number Publication date
WO2020076996A1 (en) 2020-04-16
EP3863642A1 (en) 2021-08-18
CN120468320A (zh) 2025-08-12
US20210369731A1 (en) 2021-12-02
CN113164495B (zh) 2025-04-22
JP2025072508A (ja) 2025-05-09
JP2022512643A (ja) 2022-02-07
CN113164495A (zh) 2021-07-23
US20250120982A1 (en) 2025-04-17
US12161648B2 (en) 2024-12-10
EP3863642A4 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
JP7631191B2 (ja) Ｅ３リガーゼの共有結合による標的化
US20250059187A1 (en) Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
JP6389884B2 (ja) 癌を治療するための方法及び組成物
US20130245032A1 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods of their use
Zhang et al. Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells
KR20210047981A (ko) 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
CA3172987A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
KR20180035905A (ko) Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
CN101720315B (zh) PsammaplinA的衍生物、其合成方法以及其用于预防或治疗癌症的用途
CN107849050A (zh) 化合物
Miao et al. A novel harmine derivative, N-(4-(hydroxycarbamoyl) benzyl)-1-(4-methoxyphenyl)-9H-pyrido [3, 4-b] indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects
US11767298B2 (en) Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
CA3113547A1 (en) Usp7 inhibition
Salem et al. Novel 2-substituted-quinoxaline analogs with potential antiproliferative activity against breast cancer: insights into cell cycle arrest, topoisomerase II, and EGFR activity
CN105979941A (zh) 用于治疗癌症的hdac8抑制剂
Zhu et al. Discovery of novel 5-cyano-3-phenylindole-based LSD1/HDAC dual inhibitors for colorectal cancer treatment
JP2024511466A (ja) Ａｌｋ－５阻害剤及びその使用
CA3174972A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
Liu et al. Discovery of potent HDAC6-selective inhibitors based on artemisinin: design, synthesis, and antitumor evaluation
WO2023220722A2 (en) Pak1 degraders and methods of use thereof
EP3576745A1 (en) Agents that inhibit ngly1 and methods of use thereof
Lin et al. Evaluation of chidamide and PFI-1 as a combination therapy for triple-negative breast cancer
EP4516790A1 (en) Covalent targeting of rhoa for cancer therapy
Chang Development of Proteolysis Targeting Chimeras Prodrugs Targeting Cancer and Senescence

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250205

R150 Certificate of patent or registration of utility model

Ref document number: 7631191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150